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THE EVIDENCE RELATING BLOODpressure to salt intake in hu-mans originates from popula-tion-based studies1 and ran-
domized clinical trials of interventions
on dietary salt intake.2,3 Across 52
INTERSALT centers, the median 24-
hour urinary sodium excretion ranged
from 0.2 to 242.1 mmol.1 After stan-
dardization for sex and age and with ad-
justments for body mass index and al-
cohol intake, the cross-sectionally
assessed age-related increase in sys-
tolic and diastolic blood pressure was
significantly steeper with higher so-
dium excretion. Subsequent analyses,
which accounted for regression dilu-
tion bias and included complex curve
fitting, confirmed the first INTERSALT
report.4 In a meta-analysis of 31 trials
with a minimum duration of 4 weeks,
lowering 24-hour urinary sodium ex-
cretion by 75 mmol was associated with
decreases in blood pressure, averag-
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Context Extrapolations fromobservational studies and short-term intervention trials sug-
gest that population-wide moderation of salt intake might reduce cardiovascular events.
Objective To assess whether 24-hour urinary sodium excretion predicts blood pres-
sure (BP) and health outcomes.
Design, Setting, and Participants Prospective population study, involving 3681
participantswithout cardiovascular disease (CVD)who aremembers of families thatwere
randomly enrolled in the Flemish Study on Genes, Environment, and Health Outcomes
(1985-2004) or in the European Project onGenes inHypertension (1999-2001).Of 3681
participants without CVD, 2096 were normotensive at baseline and 1499 had BP and
sodium excretion measured at baseline and last follow-up (2005-2008).
Main Outcome Measures Incidence of mortality and morbidity and association
between changes in BP and sodium excretion. Multivariable-adjusted hazard ratios
(HRs) express the risk in tertiles of sodium excretion relative to average risk in the whole
study population.
Results Among 3681 participants followed up for amedian 7.9 years, CVD deaths de-
creased across increasing tertiles of 24-hour sodium excretion, from 50 deaths in the low
(mean, 107 mmol), 24 in the medium (mean, 168 mmol), and 10 in the high excretion
group (mean, 260mmol; P.001), resulting in respective death rates of 4.1% (95%con-
fidence interval [CI], 3.5%-4.7%), 1.9% (95% CI, 1.5%-2.3%), and 0.8% (95% CI,
0.5%-1.1%). In multivariable-adjusted analyses, this inverse association retained signifi-
cance (P=.02): the HR in the low tertile was 1.56 (95% CI, 1.02-2.36; P=.04). Baseline
sodium excretion predicted neither total mortality (P=.10) nor fatal combined with non-
fatal CVD events (P=.55). Among 2096 participants followed up for 6.5 years, the risk
of hypertension did not increase across increasing tertiles (P=.93). Incident hypertension
was 187 (27.0%; HR, 1.00; 95%CI, 0.87-1.16) in the low, 190 (26.6%; HR, 1.02; 95%
CI, 0.89-1.16) in the medium, and 175 (25.4%; HR , 0.98; 95% CI, 0.86-1.12) in the
high sodiumexcretion group. In 1499 participants followed up for 6.1 years, systolic blood
pressure increased by 0.37 mm Hg per year (P .001), whereas sodium excretion did
not change (–0.45 mmol per year, P=.15). However, in multivariable-adjusted analyses,
a 100-mmol increase in sodium excretion was associated with 1.71 mm Hg increase in
systolic blood pressure (P.001) but no change in diastolic BP.
Conclusions In this population-based cohort, systolic blood pressure, but not dia-
stolic pressure, changes over time aligned with change in sodium excretion, but this
association did not translate into a higher risk of hypertension or CVD complications.
Lower sodium excretion was associated with higher CVD mortality.
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ing 5.06 mm Hg for systolic and 2.70
mm Hg for diastolic among patients
with hypertension; and by 2.03 mm Hg
and 0.99 mm Hg, respectively, among
participants without hypertension.3
Three recent reports,5-7 using statisti-
cal modeling based on the aforemen-
tioned evidence and a set of complex
assumptions, concluded that modest
reductions in dietary salt intake, in the
order of 3 g/d, could substantially reduce
cardiovascular events and medical costs.
However, theseprojections5-7 ignoredthe
inconsistency of the association between
bloodpressureandvarious indexesofsalt
intake in observational studies,8,9 the far-
reaching extrapolations from short-
term intervention trials in normoten-
sive or hypertensive volunteers to the
generalpopulation,10 thepossibleadverse
effects of an indiscriminate reduction of
salt intake,11 and the doubtful feasibility
of a generalized limitation of salt con-
sumption.12,13 Theassumptionthat lower
salt intake would in the long run lower
blood pressure, to our knowledge, has
not yet been confirmed in longitudinal
population-based studies. We addressed
these issues in randomly selected Euro-
peanpopulationsamples.Westudiedthe
incidenceofmortalityandmorbidityand
the incidence of hypertension in rela-
tion to 24-hour urinary sodium excre-
tion at baseline. We examined cross-
sectionally and longitudinally the
association between blood pressure and
24-hour urinary sodium.
METHODS
Study Population
Recruitment for the Flemish Study on
Environment, Genes, and Health Out-
comes (FLEMENGHO) started in
1985.14 From August 1985 to Novem-
ber 1990, a random sample of the
households living in a geographically
defined area of Northern Belgium was
investigated with the goal to recruit an
equal number of participants in each of
6 subgroups by sex and age (20-39, 40-
59, and 60 years). All household
members aged 20 years or older were
invited, provided that the quota of their
sex-age group had not yet been satis-
fied. From June 1996 until January
2004 recruitment of families contin-
ued using the former participants
(1985-1990) as index persons and also
including teenagers.14 The partici-
pants were repeatedly followed up. In
all study phases, we used the same stan-
dardized methods to measure clinical
and biochemical variables, administer
questionnaires, and determine inci-
dence of fatal and nonfatal out-
comes.15 The European Project on
Genes in Hypertension (EPOGH) re-
cruited participants from 1999 to
2001.16 The EPOGH investigators were
trained at the Studies Coordinating
Centre in Leuven, Belgium, and ap-
plied the same protocol, question-
naires, and follow-up procedures, as
used in FLEMENGHO.16 Question-
naires were translated from Dutch into
Czech, Italian, Polish, and Russian and
back translated into Dutch to ensure
that all questions had the same mean-
ing in all languages. At baseline the par-
ticipants collected a 24-hour urine
sample. The last follow-up examina-
tion, which also included a 24-hour
urine sampling, took place from 2005
to 2008 in FLEMENGHO and from
2006 to 2008 in EPOGH, both of which
studies were conducted according to the
principles outlined in the Helsinki
Declaration for Investigation of Hu-
man Participants.17 Each local institu-
tional review board approved the study
protocol. Participants provided writ-
ten informed consent.
Definition of Cohorts
As shown in the flow chart (FIGURE 1),
4547 participants took part in the study,
3360 in FLEMENGHO and 1187 in
Figure 1. Flowchart for Participants in the Study
3187 Invited for follow-up
2856 Agreed to participate
Blood pressure cohort
1499 Included in analysis of the relationship
between blood pressure and 24-h
urinary sodium
Hypertension cohort
2096 Included in analysis of incidence
of hypertension
3934 Individuals were invited to participate
in the Flemish Study on Environment,
Genes, and Health Outcomes
3360 Agreed to participate
1721 Individuals were invited to participate
in the European Project on Genes
in Hypertension
1187 Agreed to participate
760 Excluded (had hypertension at baseline)1357 Excluded
588 Had missing urinary collection
170 Had inaccurate urinary data 
593 Received antihypertensive
treatment
6 Had cardiovascular disease
686 Were excluded
574 Had missing urinary collection
68 Had inaccurate urinary data 
44 Had cardiovascular disease
180 Were excluded
137 Had missing urinary collection
35 Had inaccurate urinary data 
8 Had cardiovascular disease
494 Lost to follow-up
259 Moved
219 Died
16 Were seriously ill
Outcome cohort 
3681 With full set of baseline measurements
included in analysis of mortality and
morbidity
Outcome cohort, hypertension cohort, and blood pressure cohort refer to participants used to study the inci-
dence of mortality andmorbidity, the incidence of hypertension, and the changes in blood pressure over follow-
up, respectively. See “Methods” section for the definition of inaccurate urine collections.8
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EPOGH. We excluded, respectively,
642 and 172 because their baseline 24-
hour urine collection was either miss-
ing or unreliable. Inaccurate urine col-
lections were defined as a volume less
than 300 mL per 24 hours, a 24-hour
creatinine excretion of less than 4 mmol
or higher than 25 mmol in women and
less than 6 mmol or more than 30 mmol
in men.8 To study the incidence of mor-
tality and morbidity in relation to so-
dium excretion, we excluded an addi-
tional 44 FLEMENGHO and 8 EPOGH
participants because they had a his-
tory of cardiovascular disease. The out-
come cohort, therefore, included 3681
participants. During follow-up, 219 par-
ticipants died, 16 became seriously ill,
and 259 moved out of the study areas,
potentially leaving 3187 participants,
2856 (89.6%) of whom agreed to take
part in the follow-up examinations. Af-
ter exclusion of 760 patients with hy-
pertension at baseline, the hyperten-
s ion cohort cons is ted of 2096
participants (Figure 1). To study the re-
lation between blood pressure and 24-
hour urinary sodium, both cross-
sectionally and longitudinally over time,
we excluded 588 and 170 participants
whose 24-hour urine collection at fol-
low-up was either missing or unreli-
able, 593 participants taking antihy-
pertensive drug treatment at baseline,
or at follow-up, and 6 untreated par-
ticipants who at follow-up had devel-
oped cardiovascular disease. The blood
pressure cohort comprised 1499 un-
treated participants without CVD at
baseline and follow-up (Figure 1).
Measurements
Experienced observers measured each
participant’s blood pressure at baseline
and follow-up by auscultation of the
Korotkoff sounds. After the partici-
pants had rested for 5 minutes in the sit-
ting position, they obtained 5 consecu-
tive blood pressure readings (phase V
diastolic pressure) to the nearest 2
mm Hg, using mercury sphygmoma-
nometers. Standard cuffs had a 1224
cm inflatable portion, but if upper arm
girth exceeded 31 cm, larger cuffs with
1535 cm bladders were used. For
analysis, the 5 blood pressure readings
obtained at baseline or at follow-up were
averaged. Digit preference was checked
at 6-month intervals.16 Hypertension was
defined as untreated blood pressure
equal to or exceeding 140 mm Hg sys-
tolic or 90 mm Hg diastolic or the use
of antihypertensive drugs.
On average, 1 week after blood pres-
sure measurement (median, 5; range,
0-17 days at baseline; median, 3 days;
range, 0-15 days at follow-up), partici-
pants collected an exactly timed 24-
hour urine sample in a 2500 mL wide-
neck plastic container (Sarstedt article
number 77.576, Nu¨mbrecht, Ger-
many). Sodium and potassium in urine
were determined by flame photom-
etry and creatinine by an automated en-
zymatic method at certified laboratories.
Overweight was considered a body
mass index, calculated as weight in ki-
lograms divided by height in meters
squared, of 25 to less than 30; obesity,
30 or higher. The observers adminis-
tered the same questionnaire at base-
line and follow-up to collect each par-
ticipant’s medical history; smoking
status; drinking habits; medication use,
including contraceptive and hormone
replacement therapy; and educational
attainment. Venous blood samples were
drawn for blood glucose and serum total
cholesterol measurement. Diabetes
mellitus was determined by self-
reported diagnosis, fasting glucose level
of at least 126 mg/dL or random blood
glucose level of 200 mg/dL, or use of
antidiabetic agents.18 (To convert glu-
cose from mg/dL to mmol/L, multiply
by 0.0555; sodium from mmol/d to g/d
multiply by 0.02299.)
Assessment of Outcome
In each country, outcomes were adju-
dicated against source documents,
as described in previous publica-
tions.15,19 The adjudication process was
the same for both cohorts. We ascer-
tained vital status of FLEMENGHO par-
ticipants through December 31, 2009,
and of EPOGH participants through
August 15, 2008. We obtained the In-
ternational Classification of Disease
codes for the immediate and underly-
ing causes of death.19 For 2856 partici-
pants, we also collected information on
the incidence of nonfatal events via fol-
low-up visits with repeat administra-
tion of the same standardized question-
naire used at baseline. Follow-up data
were available for 329 FLEMENGHO
participants from 1; 639 from 2; and
1229 from 3 or more follow-up visits
and for 659 EPOGH participants from
1 follow-up visit. Physicians ascer-
tained the diseases reported on the
death certificates or by the question-
naires against the medical records of
general practitioners or hospitals. Fa-
tal and nonfatal stroke did not include
transient ischemic attacks. Coronary
events included fatal and nonfatal myo-
cardial infarction and coronary revas-
cularization. Fatal and nonfatal cardio-
vascular events comprised coronary end
points, stroke, fatal and nonfatal left
ventricular heart failure, aortic aneu-
rysm, cor pulmonale, and pulmonary
or arterial embolism. Hospitalizations
for unstable angina were coded as is-
chemic heart disease. Heart failure was
either a clinical diagnosis or the diag-
nosis on the death certificate but was
in all cases validated against hospital
files or the records held by family phy-
sicians. For all end points, we cen-
sored participants from analysis after
the occurence of a first event.
Statistical Analysis
For database management and statis-
tical analysis, we used SAS software,
version 9.1.3 with the JMP add-on, ver-
sion 8 (SAS Institute Inc, Cary, North
Carolina). Departure from normality
was evaluated by Shapiro-Wilk statis-
tic and skewness by the computation
of the coefficient of skewness, namely
the third moment about the mean
divided by the cube of the standard
deviation. We computed 95% confi-
dence intervals (CIs) of rates as
R±(R/T), where R and T are the rate
and the denominator used to calculate
the rate. We compared means and pro-
portions by the standard normal z test
and the 2 statistic, respectively. Sta-
tistical significance was a 2-sided sig-
nificance level of .05.
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To explore the plausibility of the Cox
model in the outcome cohort, we plot-
ted incidence rates by tertiles of the
24-hour urinary sodium excretion at
baseline, while standardizing for study
population, sex, and age by the direct
method. In line with other studies,20-24
the assumption of a log-linear associa-
tion between outcome and the 24-hour
urinary sodium excretion at baseline
was not fulfilled. We therefore com-
pared the risk in each tertile with the
overall risk in the whole study popu-
lationusingmultipleCoxregressionand
deviation from mean coding.25 This
approach allows computation of CIs for
the hazard ratio (HR) in each tertile
without definition of an arbitrary ref-
erence group. We used Cox propor-
tional hazard regression as imple-
mented in the PROC SURVIVAL
procedureof theSUDAANsoftware (Re-
search Triangle Institute, Research Tri-
angle Park, North Carolina), version
10.01, to calculate HRs in the outcome
and hypertension cohorts, while allow-
ing for covariables and accounting for
family clusters. The baseline charac-
teristics considered as covariables in
Cox regression were study popula-
tion, sex, age, blood pressure level, body
mass index, alcohol intake, use of anti-
hypertensive drugs, urinary potas-
sium excretion, educational attain-
ment, and additionally smoking status,
total cholesterol level, and diabetes for
analyses involving the outcome cohort.
For the blood pressure cohort, we
used the t test and the McNemar test
to evaluate changes from baseline to fol-
low-up in continuous and categorical
variables, respectively. Our statistical
methods also included single and mul-
tiple linear regressions. We included in
our model covariables with known
physiological relevance for blood pres-
sure. We applied a generalization of the
standard linear model, as imple-
mented in the PROC MIXED proce-
dure of the SAS package, to investi-
gate the associations between blood
pressure and explanatory variables,
while accounting for family clusters and
adjusting for covariables. We defined
absolute change as a difference be-
tween follow-up and baseline values,
and relative (percentage) change as the
absolute change divided by baseline
value multiplied by 100.
RESULTS
Characteristics at Baseline
by Cohort
TABLE 1 lists the baseline characteris-
tics of the whole study population by
cohort. Baseline characteristics are pro-
vided in eTables 1 and 2 for the out-
come cohort and in eTables 3 and 4 for
the hypertension cohort (available at
http://www.jama.com) by tertiles of the
urinary sodium excretion and by sex.
eTable 5 describes the baseline and fol-
low-up characteristics of the blood pres-
sure cohort by country. All partici-
pants were white Europeans. From
72.6% to 78.4% of participants were re-
cruited in Flanders. The 3 cohorts in-
cluded just more than 50% of women.
Analysis of Outcome
In the outcome cohort, median fol-
low-up was 7.9 years. During 39 780
person-years of follow-up, 219 partici-
pants died (5.51 deaths per 1000 person-
years), and 232 experienced a fatal or
Table 1. Baseline Characteristics of Study Participants by Cohorta
Characteristics
Cohort
Outcome
(n = 3681)
Hypertension
(n = 2096)
Blood Pressure
(n = 1499)
Follow-up, median (IQR), y 7.93 (6.35-17.20) 6.48 (5.13-9.19) 6.14 (5.14-7.93)
Participant characteristics, No. (%)
FLEMENGHO 2674 (72.6) 1644 (78.4) 1109 (74.0)
EPOGH 1007 (27.4) 452 (21.6) 390 (26.0)
Women 1941 (52.7) 1133 (54.1) 786 (52.4)
Hypertension 949 (25.8) 148 (9.9)
Diabetes mellitus 152 (4.1) 40 (1.9) 29 (1.9)
Antihypertensive treatment 443 (12.0)
Use of female sex hormones 381 (10.4) 250 (11.9) 165 (11.0)
Use of NSAIDs 502 (13.6) 283 (13.5) 185 (12.3)
Educational attainment, No. (%)
Elementary school 1210 (32.9) 679 (32.4) 437 (29.1)
Secondary school 1896 (51.5) 1118 (53.3) 854 (57.0)
Higher education 575 (15.6) 299 (14.3) 208 (13.9)
Smokers, No. (%) 1044 (28.4) 653 (31.2) 455 (30.4)
Alcohol intake5 g/d, No. (%) 886 (24.1) 465 (22.2) 345 (23.0)
Characteristic, mean (SD)
Age, y 40.9 (16.3) 38.6 (14.6) 38.3 (14.2)
Blood pressure, mm Hgb
Systolic 124.7 (17.1) 118.7 (10.4) 120.9 (12.8)
Diastolic 76.3 (10.6) 73.3 (8.0) 74.6 (8.9)
BMI 25.2 (4.6) 24.5 (4.0) 24.6 (4.0)
Total cholesterol, mg/dL 209 (46) 207 (46) 207 (42)
24-h urinary measurements, mean (SD)
Duration, h:m 23:52 (00:59) 23:51 (01:02) 23:48 (01:08)
Volume, L 1.52 (0.64) 1.52 (0.65) 1.54 (0.65)
Sodium, mmol 178.0 (74.8) 174.2 (74.1) 172.7 (62.5)
Potassium, mmol 66.2 (26.3) 66.8 (25.5) 66.3 (22.4)
Sodium-to-potassium ratio 2.93 (1.56) 2.81 (1.27) 2.78 (1.12)
Creatinine, mmol 11.6 (3.9) 11.7 (3.8) 11.9 (3.7)
Abbreviations: BMI, bodymass index,which is calculated asweight in kilogramsdividedby height inmeters squared; EPOGH,
the European Project on Genes in Hypertension; FLEMENGHO, the Flemish Study on Environment, Genes, and Health
Outcomes; IQR, interquartile range; NSAID, nonsteroid antiinflammatory drug.
SI conversion factors: To convert sodium from mmol to g, multiply by 0.02299; potassium from mmol to g, multiply by
0.039098; creatinine from mmol to g, multiply by 0.11312; cholesterol from mg/dL to mmol/L, multiply by 0.0259.
aOutcome cohort, hypertension cohort, and blood pressure cohort refer to participants used to study the incidence of
mortality and morbidity, the incidence of hypertension, and the changes in blood pressure over follow-up, respectively
(see Figure 1). See “Methods” section for details of each study.
bFor thebloodpressuredeterminationand thediagnosesof hypertensionanddiabetesmellitus, see the “Methods” section.
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nonfatal cardiovascular complication
(5.83 events per 1000 person-years).
Mortality included 84 cardiovascular and
135 noncardiovascular deaths. eTable 6
lists thecause-specificmortality andmor-
bidity for the entire outcome cohort and
in the FLEMENGHO and EPOGH study
populations, separately.
FIGURE2showsKaplan-Meiersurvival
function estimates for cardiovascular
mortality and the composite cardiovas-
cularendpoints intertilesof the24-hour
urinarysodiumexcretion.Cardiovascu-
lar deaths decreased across increasing
tertilesof24-hoururinarysodium: from
50 in the low (death rate, 4.1%; 95% CI,
3.5%-4.7%), 24 in the medium, (death
rate, 1.9%; 95% CI, 1.5%-2.3%); and 10
in thehigh tertile (death rate,0.8%,95%
CI,0.5%-1.1%;P .001).Themean24-
hour urinary sodium excretion for each
tertile was defined as 106 mmol for the
low,165mmol for themedium;and250
mmol for the high tertile.
EFigure 1 (available at http://www
.jama.com) shows standardized rates of
mortality and combined fatal and non-
fatal outcomes across tertiles. TABLE 2
shows the multivariable-adjusted HRs
expressing the risk in each tertile of the
sex-specific distribution of the 24-
hour urinary sodium excretion com-
pared with the overall risk in the whole
outcome cohort. The risk of cardiovas-
cular mortality was significantly
elevated in the low tertile (HR, 1.56;
95% CI, 1.02-2.36; P=.04) with a sig-
nificant inverse association between
Figure 2. Kaplan-Meier Survival Function Estimates for Cardiovascular Mortality and All
Cardiovascular Events
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Tertiles of 24-hour urinary sodium excretion are sex-specific based on baseline measures (see Table 2). This
analysis includes the outcome cohort (see Figure 1 and Table 1). Regions of y-axis scales drawn in blue indi-
cate range from 0 to 5.
Table 2. Mortality and Cardiovascular Events by Tertiles of the 24-Hour Urinary Sodium Excretion at Baseline
24-Hour Urinary Sodium Excretion Tertiles at Baseline
Low
(n = 1220)
Medium
(n = 1250)
High
(n = 1211)
No. of women 645 658 638
Range, mmol 50-126 127-177 178-400
Mean (SD), mmol 95.1 (22.0) 150.2 (15.0) 231.7 (50.9)
No. of men 575 592 573
Range, mmol 50-158 159-221 222-400
Mean (SD), mmol 120.1 (28.4) 188.8 (17.6) 290.5 (56.2)
Total No. of
Events of
Outcome Cohort
No. of
Events
Adjusted HR
(95% CI)a
No. of
Events
Adjusted HR
(95% CI)a
No. of
Events
Adjusted HR
(95% CI)a
P
Value
Mortality
All causes 219 118 1.14 (0.87-1.50) 64 0.94 (0.75-1.18) 37 1.06 (0.84-1.33) .10
Cardiovascular 84 50 1.56 (1.02-2.36)b 24 1.05 (0.72-1.53) 10 0.95 (0.66-1.38) .02
Noncardiovascular 135 68 0.98 (0.71-1.36) 40 0.90 (0.68-1.20) 27 1.11 (0.83-1.47) .64
Fatal and nonfatal events
All cardiovascular 232 100 1.13 (0.90-1.42) 79 1.11 (0.90-1.36) 53 0.90 (0.73-1.11) .55
Coronary 98 45 1.42 (0.99-2.04) 34 1.17 (0.89-1.54) 19 0.86 (0.65-1.13) .10
Stroke 33 13 1.07 (0.57-2.00) 13 1.29 (0.75-2.20) 7 0.78 (0.45-1.33) .64
Abbreviations: CI, confidence interval; HR, hazard ratio.
This analysis includes the outcome cohort (see Figure 1 and Table 1).
aHazard ratios were computed by deviation from mean coding25 and express the risk in each tertile of the distribution of 24-hour urinary sodium excretion at baseline compared with the
overall risk in the whole outcome cohort. We applied Cox proportional hazard regression to derive HRs, while allowing for covariables and accounting for family clusters. All HRs were
adjusted for study population, sex, and baseline variables: age, bodymass index, systolic blood pressure, 24-hour urinary potassium excretion, antihypertensive drug treatment, smok-
ing and drinking alcohol, diabetes, total cholesterol, and educational attainment. Adjustment for diastolic blood pressure or mean arterial pressure did not materially alter the findings.
P values are for linear trend across the tertiles of 24-hour sodium excretion.
bP=.04.
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cardiovascular mortality and tertile of
sodium excretion (P=.02).
In sensitivity analyses involving car-
diovascular mortality in relation to sex-
specific tertiles of 24-hour urinary so-
dium stratified for age (60 vs 60
years), there were 18 deaths (eTable 7;
available at http://www.jama.com) in
the younger age group and 66 deaths
(eTable 8) in the older age group. The
HRs in the low tertiles were 1.41 (95%
CI, 0.70-2.83, P=.33) for the younger
group and 1.52 (95% CI, 0.94-2.47,
P=.09) for the older group. Models not
including adjustment for systolic blood
pressure at baseline (eTable 9) or using
24-hour urinary sodium-to-potas-
sium ratio at baseline as the exposure
variable (eTable 10) produced consis-
tent results for cardiovascular mortal-
ity. By censoring the adjusted Cox mod-
els for cardiovascular mortality at 6, 9,
12, 15, 18, and 21 years, we further-
more explored whether the risk in the
low tertile changed with longer fol-
low-up (eTable 11). The HRs were 1.65
(95% CI, 0.85-3.22, P=.14) at 6 years,
1.20 (95% CI, 0.54-2.63, P=.65) at 9
years, 1.61 (95% CI, 0.77-3.35, P=.20)
at 12 years, 1.68 (95% CI, 0.88-3.20,
P=.12) at 15 years, 1.66 (95% CI, 1.00
-2.75, P=.048) at 18 years, and 1.56
(95% CI, 1.02-2.36, P= .039) at 21
years. Excluding cardiovascular deaths
that occurred within 3 years of enroll-
ment did not remove significance from
the HR in the low tertile (1.67; 95% CI,
1.05-2.68; P=.03).
Incidence of Hypertension
The median follow-up was 6.5 years in
the hypertension cohort. There were
552 cases of incident hypertension. Un-
adjusted Kaplan-Meier survival func-
tion estimates (eFigure 2) and multi-
variable-adjusted HRs (eTable 12)
showed that baseline 24-hour urinary
sodium did not predict the incidence
of hypertension. In the entire hyper-
tension cohort, across increasing ter-
tiles of urinary sodium, the number of
incident cases amounted to 187 (27.0%;
HR, 1.00; 95% CI, 0.87-1.16; P=.95) in
the low, 190 (26.6%; HR, 1.02; 95% CI,
0.89-1.16, P=.79) in the medium, and
175 (25.4%; HR, 0.98; 0.86-1.12,
P=.78) in the high tertile.
Cross-sectional Analysis
of Blood Pressure
In minimally adjusted analyses, in which
we accounted only for country, sex, age,
and family clusters, most associations of
systolic and diastolic blood pressures
with 24-hour urinary sodium excre-
tion were significant at baseline as well
as at follow-up. In fully adjusted mod-
els (eTable 13), the cross-sectional as-
sociations of systolic blood pressure with
the 24-hour urinary sodium remained
significant for the entire blood pres-
sure cohort at baseline and follow-up
and for EPOGH participants at base-
line and for FLEMENGHO partici-
pants at follow-up. For the entire blood
pressure cohort, a 100-mmol increase in
the 24-hour urinary sodium excretion
was associated with increases in sys-
tolic pressure of 1.14 mm Hg at base-
line and 1.46 mm Hg at follow-up. In
fully adjusted models, the cross-
sectional associations of diastolic blood
pressure with 24-hour urinary sodium
excretion lost significance at baseline as
well as at follow-up (eTable 13).
Longitudinal Analysis
of Blood Pressure
During 6.1 years of follow-up, systolic
and diastolic blood pressures in-
creased significantly in all centers ex-
cept for systolic blood pressure in Pilsen
(eTable 5). The annual changes for the
entire blood pressure cohort averaged
(SE) 0.37 (0.051) mm Hg systolic and
0.47 (0.039) mm Hg diastolic (P .001
for both). Untreated hypertension was
present in 148 participants (9.9%) at
baseline and 298 (19.9%) at follow-
up. Of 1351 initially normotensive par-
ticipants, 204 (15.1%) became hyper-
tensive during follow-up. Of 148
initially hypertensive participants, 54
(36.5%) were reclassified as normoten-
sive at follow-up (McNemar statistic,
87.2; P .001).
The 24-hour urinary sodium excre-
tion remained unchanged during fol-
low-up (P=.15). Only in Krako´w did
the 24-hour urinary sodium excretion
decrease by a mean (SE) of 6.27 mmol
(1.04 mmol) per year (P .001). The
absolute and relative changes in sys-
tolic and diastolic pressures and 24-
hour urinary sodium were not nor-
mally distributed for the entire blood
pressure cohort (Shapiro-Wilk statis-
tic 0.92; P .001; eFigure 3).
Changes in systolic blood pressure
during follow-up were positively re-
lated to the corresponding changes in 24-
hour urinary sodium in the entire blood
pressure cohort and FLEMENGHO par-
ticipants (TABLE 3). In absolute terms,
a 100-mmol increase in the 24-hour uri-
nary sodium excretion over follow-up
was associated with a 1.71 mm Hg in-
crease in systolic blood pressure
(P .001), while accounting for family
cluster, and with adjustments applied for
study population, sex, and baseline val-
ues of changes in age, body mass index,
and alcohol intake (stopping, no change,
and starting; –1,0,1), 24-hour urinary po-
tassium excretion, use of female sex ste-
roids (–1,0,1), and use of nonsteroidal
anti-inflammatorydrugs (–1,0,1). In rela-
tive terms, a doubling of the 24-hour uri-
nary sodium excretion was associated
with 2.2% increase in systolic blood pres-
sure (P .001; Table 3). In these multi-
variable-adjusted analyses, the associa-
tions between the changes in diastolic
blood pressure and 24-hour urinary so-
dium did not reach significance in ab-
solute or relative terms. EFigures 4 and
5 illustrate the aforementioned multi-
variable-adjusted changes in systolic and
diastolic blood pressure by deciles of the
changes in 24-hour urinary sodium.
COMMENT
In multivariable-adjusted models sys-
tolic pressure, but not diastolic pres-
sure, was positively and independently
correlated with the 24-hour urinary
sodium excretion. This correlation was
present at baseline and follow-up in the
whole studypopulationbutwasnotcon-
sistent among FLEMENGHO and
EPOGH participants. A key finding was
that in longitudinal analyses, systolicbut
not diastolic blood pressure changed in
line with the change in urinary sodium
excretion. However, this association did
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not translate into a higher risk of hyper-
tension or cardiovascular complica-
tions. In contrast, we found a weak but
consistent inverse association between
cardiovascularmortalityandthe24-hour
urinary sodium excretion at baseline.
In the blood pressure cohort, so-
dium excretion, on average, did not
change in any country with the excep-
tion of Poland, where at baseline it was
higher than in any other study site. This
observation is in keeping with the lack
of changes in urinary sodium excre-
tion in 38 US studies conducted over
46 years (1957-2003)26 and in 13 sur-
veys carried out in the United King-
dom over 25 years (1984-2008).27 These
studies26,27 along with our current re-
sults support the concept that sodium
intake is difficult to manipulate and is
regulated27 to maintain the concentra-
tion of extracellular and serum so-
dium within a narrow range. Exchange-
able sodium is increased in hypertensive
patients and correlates positively with
arterial pressure,28 but patients with pri-
mary hypertension do not have a larger
extracellular fluid volume, plasma vol-
ume, or blood volume compared with
normotensive controls.29
In the longitudinal analysis of the
blood pressure cohort, systolic pres-
sure increased by 1.71 mm Hg for a 100-
mmol per day increment in urinary so-
dium, whereas diastolic pressure
remained unaffected. Two meta-
analyses10,30 reported blood pressure re-
sponses to salt restriction of similar mag-
nitude in normotensive individuals. The
effect sizes were 1.0 mm Hg systolic
(P .001) and 0.1 mm Hg diastolic
(P=.64) per 100-mmol decrease in 24-
hour urinary sodium30 or 1.2 mm Hg
systolic (P .001) and 0.26 mm Hg dia-
stolic (P=.12) per 160 mmol.10 In a
meta-regression analysis by He and
MacGregor,31 a reduction of salt intake
by 3 g/d predicted a decrease in systolic/
diastolic blood pressure by 3.6 to 5.6/
1.9 to 3.2 mm Hg in hypertensive pa-
tients and by 1.8 to 3.5/0.8 to 1.8 mm Hg
in normotensive participants. Systolic
pressure increases with age at least un-
til the eighth decade of life, whereas dia-
stolic pressure increases until age 50
years and thereafter either levels off or
slightly decreases.32 In long-term stud-
ies such as ours, these divergent age-
related systolic and diastolic trends
might attenuate or mask any trends in
blood pressure associated with changes
in 24-hour urinary sodium.
Several prospective studies dealt with
the effects of salt intake on the inci-
dence of hypertension or cardiovascu-
lar complications, but few21,33-36 based
their assessments on 24-hour urinary
sodium excretion, the most accurate ap-
proach to assess salt intake. None de-
scribed the longitudinal association be-
tween changes in blood pressure on a
continuous scale in relation to changes
in 24-hour urinary sodium excretion.
He and colleagues34 examined the ef-
fects of reducing salt intake on the in-
cidence of hypertension for 128 par-
ticipants. During the randomized
intervention of 18 months the between-
group gradient in 24-hour urinary so-
dium excretion averaged 33 mmol. Af-
ter an average of 7 years of follow-up
without any intervention, the multi-
variable adjusted odds of hyperten-
sion for active intervention vs control
was 0.65 but in line with our findings,
it did not reach significance (95% CI,
0.25-1.69; P=.37).34 In a 7-year study
involving 233 randomly selected chil-
dren, no association was found be-
tween the changes in blood pressure
and salt intake that was extrapolated
from overnight urine samples that were
repeatedly collected during follow-
up, with sodium excretion rates aver-
aged for analysis.37
In our current study, cardiovascular
mortality was significantly elevated in the
low tertile of 24-hour urinary sodium ex-
cretion with a significant inverse asso-
ciation with sodium excretion across ter-
tiles. It isunlikely that these findingswere
due to reverse causality because we ex-
cluded patients with a history of CVD.
Moreover, these observations were con-
sistent when we censored cardiovascu-
lar deaths over a time span ranging from
6 to 21 years, or excluded cardiovascu-
lar deaths occurring within 3 years of en-
rolment. Similarly, models including or
excluding systolic pressure as covari-
able produced consistent results. Our
current observations on cardiovascular
mortality are consistent with several
other reports.33,38-40 The National Health
and Nutrition Examination Surveys
(NHANES) I38 and II39 demonstrated an
inverse association of cardiovascular and
total mortality with salt intake as as-
sessed from dietary recall with a similar
trend in NHANES III.40 Alderman and
colleagues33 followed up for 3.5 years
2937 patients with mild to moderate hy-
pertension. There was an inverse asso-
ciation between the incidence of myo-
cardial infarction and 24-hour urinary
sodium excretion at baseline for the total
population and for men, but not women.
For men, the race- and age-adjusted HR
expressing the risk in the lowest vs the
Table 3. Multivariable Adjusted Longitudinal Associations Between Changes in Blood
Pressure and 24-Hour Urinary Sodium by Study Populationa
Study Population
Absolute Relative
Estimates
(95% CI)b
P
Value
Estimates
(95% CI)b
P
Value
Change in systolic pressure
FLEMENGHO 2.373 (1.154 to 3.392) .001 2.740 (1.410 to 4.069) .001
EPOGH 0.196 (–1.409 to 1.801) .81 0.085 (–2.181 to 2.351) .94
All 1.711 (0.786 to 2.637) .001 2.211 (1.059 to 3.364) .001
Change in diastolic pressure
FLEMENGHO 0.576 (–0.246 to 1.398) .17 1.476 (–0.113 to 3.065) .07
EPOGH –0.052 (–1.317 to 1.212) .94 –0.175 (–3.064 to 2.714) .90
All 0.379 (–0.313 to 1.070) .28 1.107 (–0.279 to 2.492) .12
Abbreviations: CI, confidence interval; EPOGH, the European Project on Genes in Hypertension; FLEMENGHO, Flemish
Study on Environment, Genes, and Health Outcomes.
aReasons for exclusion from analysis are explained in the “Methods” section.
bEstimates and 95% CIs express the change in systolic blood pressure per 100-millimole increase in 24-hour urinary so-
dium excretion or the percentage change in systolic pressure for a doubling of 24-hour urine sodium. Parameter adjust-
ment definitions are in the “Results” section. Estimates for all participants were adjusted for study population.
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highest quartile of 24-hour urinary so-
dium was 4.3 (95% CI, 1.7-10.6). Other
investigators criticized Alderman’s find-
ings, because he instructed his patients
to avoid high-salt foods 4 to 5 days be-
fore sodium excretion measurements
were taken, which might have led to dis-
torted levels. In our epidemiological
study, which was conducted outside a
medical environment, participants did
not receive any recommendations from
the research team about moderating their
salt consumption. The underlying
mechanisms explaining the inverse as-
sociation between cardiovascular mor-
tality and 24-hour urinary sodium ex-
cretion might be that a salt intake low
enough to decrease blood pressure also
increases sympathetic nerve activity, de-
creases insulin sensitivity, activates the
renin-angiotensin system, and stimu-
lates aldosterone secretion.10
At variance with our current find-
ings, other prospective studies sug-
gested that a high-salt intake may lead
to a worse outcome. In the Scottish Heart
Health Study,21 24-hour urinary so-
dium predicted coronary heart disease
in women but not men. The HRs for the
lowest quintile vs the 4 other quintiles
of sodium excretion combined were 1.16
(95% CI, 1.00-1.33) and 1.05 (95% CI,
0.96-1.14), respectively. The analyses
were only adjusted for age. Cook and
colleagues36 analyzed the long-term re-
sults of dietary sodium restriction on car-
diovascular outcomes by combining 10
to 15 years of follow-up of 744 and 2382
participants randomized in the Trials of
Hypertension Prevention, phases 1 and
2. Net sodium reductions during the in-
tervention period (from 18 to 48
months) were 44 mmol and 33 mmol
per day, respectively. The follow-up for
mortality was 100%, but only 77% for
morbidity. With adjustments applied for
trial, clinical site, race, sex, and age, the
HRs for intervention vs control were
0.80 (95% CI, 0.51-1.26;P=.34) for total
mortality and 0.75 (95% CI, 0.57-
0.99) for cardiovascular events
(P=.04).36 In a 19-year follow-up study
of 3126 Fins,35 the multivariable-
adjusted HRs associated with a 100-
mmol increase in 24-hour urinary so-
dium were 1.26 (95% CI, 1.06-1.50) for
total mortality, 1.45 (95% CI, 1.14-
1.84) for CVD, and 1.51 (95% CI, 1.14-
2.00) for coronary heart disease. When
analyses were done separately for each
sex, the HRs were significant in men
only.35
In a meta-analysis including some of
the aforementioned studies, Straz-
zullo and colleagues41 reported that the
risk of stroke increased by 6% (95% CI,
3%-10%; P=.04) for an increase in so-
dium intake by 50 mmol per day. A
similar trend for CVD was not signifi-
cant (19%; 95% CI, −31%-107%;
P=.53).41 Across the reports included
in Strazzullo’s meta-analysis,41 the
methods for assessing salt intake were
not standardized. Studies with exclu-
sively fatal outcomes were pooled with
those including both fatal and nonfa-
tal events. Moreover, the HRs used in
the variance-weighted meta-regres-
sion analysis were not standardized to
the same amount of sodium.41
Our current study has to be inter-
preted within the context of its poten-
tial limitations. First, one 24-hour urine
collection might be insufficient to char-
acterize an individual’s habitual salt in-
take, but it does accurately reflect the
average salt consumption of groups of
subjects.42 Thus, our analyses based on
tertiles of 24-hour urinary sodium
should be less vulnerable to the high
intraindividual variability of sodium ex-
cretion. Second, our study population
was relatively young, so that the num-
ber of events was relatively small, lead-
ing to a potential underestimation of the
risk of excessive sodium intake. In par-
ticular, EPOGH participants were
younger than those participating in the
FLEMENGHO study and were only fol-
lowed up for a median of 6.5 years com-
pared with 10.6 years. Third, our study
included only white Europeans and its
findings therefore cannot be extrapo-
lated to Asian or in particular black in-
dividuals, who might be more salt sen-
sitive than white people.43,44 Fourth, we
did not assess sodium sensitivity. Blood
pressure responses to changes in di-
etary salt intake are heterogeneous,45
but there is no practical clinical test to
assess sodium sensitivity in individual
subjects.
In conclusion, we observed signifi-
cant cross-sectional and longitudinal as-
sociations between systolic pressure and
sodium excretion in the whole study
population. However, these associa-
tions were not consistent among
FLEMENGHO and EPOGH partici-
pants. Diastolic pressure was not cor-
related with sodium excretion. Base-
line sodium excretion did not predict
the incidence of hypertension. The as-
sociations between systolic pressure and
sodium excretion did not translate into
less morbidity or improved survival. On
the contrary, low sodium excretion pre-
dicted higher cardiovascular mortal-
ity. Taken together, our current find-
ings refute the estimates of computer
models of lives saved and health care
costs reduced with lower salt in-
take.5-7 They do also not support the
current recommendations of a gener-
alized and indiscriminate reduction of
salt intake at the population level. How-
ever, they do not negate the blood
pressure−lowering effects of a dietary
salt reduction in hypertensive pa-
tients.10,30
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eTable 1.  Characteristics of Women in the Outcome Cohorta by Tertiles of the 24-Hour Urinary Sodium Excretion at 
Baseline  
 24-Hour Urinary Sodium Excretion Tertiles       
 Low  
(n=645)  
Medium  
(n=658)  
High  
(n=638)  
Participant characteristics, No (%)      
Diabetes mellitus  21 (3.3)  19 (2.9)  31 (4.9)  
Antihypertensive treatment  96 (14.9)  82 (12.5)  106 (16.6)M  
Smokers  167 (25.9)  146 (22.2)  141 (22.1)  
Alcohol intake ≥5 g/day  69 (10.7)  68 (10.3)  89 (14.0)M  
Educational attainment, No. (%)    
≤ Elementary school  281 (43.6)  241 (36.6)  188 (29.5)  
Secondary school  289 (44.8)  318 (48.3)  327 (51.3)   
Higher education  75 (11.6)  99 (15.1)L  123 (19.3)LM  
Characteristic, mean (SD)     
Age, y  42.5 (17.6)  41.0 (16.0)  39.2 (14.7)LM  
Blood pressure, mm Hgb    
Systolic  123.3 (19.4)  121.0 (16.8)L  121.7 (15.8)  
Diastolic  74.7 (11.0)  74.6 (9.7)  75.4 (10.2)  
Weight, kg  63.4 (12.9)  65.4 (12.3)L  68.7 (13.9)LM  
BMI, kg/m2  24.6 (5.1)  24.9 (4.6)  25.9 (5.3)LM  
Total cholesterol, mg/dL  213 (51)  209 (47) 204 (45)L  
24-hour urinary measurements, mean (SD)    
Duration, h:m  23:54 (00:50)  23:47 (00:56)  23:55 (00:53)  
Volume, L  1.37 (0.64)  1.51 (0.62)L  1.67 (0.65)LM  
Sodium, mmol  95.1 (22.0)  150.2 (15.0)L  231.7 (50.9)LM  
Potassium, mmol  51.6 (17.8)  61.0 (20.5)L  69.1 (24.0)LM  
Sodium-to-potassium ratio  2.02 (0.84)  2.76 (1.19)L  3.75 (1.73)LM  
Creatinine, mmol  8.4 (2.2)  9.5 (2.0)L  10.6 (2.5)LM  
Abbreviation: BMl, body mass index, which is calculated as weight in kilograms divided by height in  
meters squared.  
Sl conversion factors: To convert millimoles of sodium to grams, multiply by 0.02299; to convert  
millimoles of potassium to grams, multiply by 0.039098; to convert millimoles of creatinine to grams, multiply by 0.11312; 
cholesterol from mg/dl to mmol/L, multiply by 0.0259.  
aThis analysis includes the Outcome Cohort (n=3681; see Figure 1 and Table 1).  
bFor the blood pressure determination and diabetes mellitus diagnosis, see the "Methods" section.  
P<.05 vs low (L) or middle (M) tertile of 24-hour urinary sodium excretion.  
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eTable 2.  Characteristics of Men in the Outcome Cohorta by Tertiles of the 24-Hour Urinary Sodium Excretion at 
Baseline  
 24-Hour Urinary Sodium Excretion Tertiles        
 Low  
(n=575)  
Medium   
(n=592)  
High  
(n=573)  
Participant characteristics, No (%)    
Diabetes mellitus  29 (5.0)  26 (4.4)  26 (4.5)  
Antihypertensive treatment  64 (11.1)  44 (7.4)L  51 (8.9)  
Smokers  202 (35.1)  221 (37.3)  167 (29.1)LM  
Alcohol intake ≥5 g/day  197 (34.3)  211 (35.6)  252 (44.0)  
Educational attainment, No. (%)    
≤ Elementary school  199 (34.6)  188 (31.8)  113 (19.7)  
Secondary school  288 (50.1)  327 (55.2)  347 (60.6)  
Higher education  88 (15.3)  77 (13.0)  113 (19.7)  
Characteristic, mean (SD)    
Age, y  41.8 (18.1)  41.3 (16.4)  39.5 (14.4)LM  
Blood pressure, mm Hgb    
Systolic  128.7 (17.9)  126.6 (14.9)L  128.1 (15.3)  
Diastolic  77.8 (11.0)  76.6 (10.4)  79.0 (10.9)M  
Weight, kg  74.1 (13.0)  76.9 (12.4)L  81.2 (14.1)LM  
BMI  24.7 (3.8)  25.2 (3.8)L  26.1 (4.3)LM  
Total cholesterol, mg/dL 205 (48) 206 (47)  205 (48)  
24-hour urinary measurements, mean (SD)      
Duration, h:m  23:51 (01:04)  23:50 (01:07)  23:54 (01:01)  
Volume, L  1.32 (0.59)  1.48 (0.57)L  1.78 (0.63)LM  
Sodium, mmol  120.1 (28.4)  188.8 (17.6)L  290.5 (56.2)LM  
Potassium, mmol  61.6 (26.3)  71.6 (27.1)L  84.5 (29.2)LM  
Sodium-to-potassium ratio  2.21 (0.93)  2.99 (1.58)L  3.89 (1.79)LM  
Creatinine, mmol  12.1 (3.2)  13.9 (3.4)L  16.1 (3.8)LM  
Abbreviation: BMl, body mass index, which is calculated as weight in kilograms divided by height in meters squared.  
Sl conversion factors: To convert millimoles of sodium to grams, multiply by 0.02299; to convert millimoles of potassium to grams, 
multiply by 0.039098; to convert millimoles of creatinine to grams, multiply by 0.11312; cholesterol from mg/dl to mmol/L, 
multiply by 0.0259.  
aThis analysis includes the Outcome Cohort (n=3681; see Figure 1 and Table 1).  
bFor the blood pressure determination and diabetes mellitus diagnosis, see the "Methods" section.  
P<.05 vs low (L) or middle (M) tertile of 24-hour urinary sodium excretion.  
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eTable 3.  Characteristics of Women in the Hypertension Cohorta by Tertiles of the 24-Hour Urinary 
Sodium Excretion at Baseline  
 24-Hour Urinary Sodium Excretion Tertiles    
 Low  
(n=375)  
Medium  
(n=385)  
High  
(n=373)  
Participant characteristics, No (%)     
Diabetes mellitus  7 (1.9)  6 (1.6)  7 (1.9)  
Smokers  121 (32.3)  91 (23.6)  89 (23.9)  
Alcohol intake 5 g/day  33 (8.8)  38 (9.9)  48 (12.9)  
Educational attainment, No. (%)    
 Elementary school  149 (39.7)  151 (39.2)  116 (31.1)  
Secondary school  186 (49.6)  179 (46.5)  194 (52.0)  
Higher education  40 (10.7)  55 (14.3)  63 (16.9)L  
Characteristic, mean (SD)    
Age, y  38.9 (15.3)  38.7 (14.1)  36.7 (13.1)LM  
Blood pressure, mm Hgb    
Systolic  115.6 (11.2)  115.6 (10.7)  116.8 (10.0)  
Diastolic  71.3 (8.0)  72.1 (7.6)  73.0 (8.0)L  
Weight, kg  61.6 (11.2)  63.7 (11.2)L  66.4 (12.4)LM  
BMI, kg/m2  23.6 (4.2)  24.1 (4.1)  25.0 (4.6)LM  
Total cholesterol, mg/dL  208 (49)  208 (47)  200 (44)LM  
24-hour urinary measurements, mean (SD)       
Duration, h:m  23:51 (00:58)  23:49 (00:55)  23:55 (00:56)  
Volume, L  1.36 (0.67)  1.52 (0.64)L  1.68 (0.67)LM  
Sodium, mmol  94.4 (21.5)  147.4 (14.3)L  222.1 (47.2)LM  
Potassium, mmol  51.2 (17.2)  62.9 (21.1)L  69.4 (23.4)LM  
Sodium-to-potassium ratio  2.00 (0.76)  2.63 (1.21)L  3.56 (1.66)LM  
Creatinine, mmol  8.6 (2.2)  9.6 (2.0)L  10.8 (2.5)LM  
Abbreviation: BMl, body mass index, which is calculated as weight in kilograms divided by height in meters 
squared.  
Sl conversion factors: To convert millimoles of sodium to grams, multiply by 0.02299; to convert millimoles of 
potassium to grams, multiply by 0.039098; to convert millimoles of creatinine to grams, multiply by 0.11312; 
cholesterol from mg/dl to mmol/L, multiply by 0.0259.  
aThis analysis includes the Hypertension Cohort (n=2096; see Figure 1 and Table 1).  
bFor the blood pressure determination and diabetes mellitus diagnosis, see the "Methods" section.  
P<.05 vs low (L) or middle (M) tertile of 24-hour urinary sodium excretion.    
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eTable 4.  Characteristics of Men in the Hypertension Cohorta by Tertiles of the 24-Hour Urinary Sodium Excretion at 
Baseline  
 24-Hour Urinary Sodium Excretion Tertiles        
 Low   
(n=318)  
Medium  
(n=328)  
High  
(n=317)  
Participant characteristics, No (%)    
Diabetes mellitus  6 (1.9)  8 (2.4)  6 (1.9)  
Smokers 120 (37.7)  128 (39.0)  104 (32.8)  
Alcohol intake ≥5 g/day 112 (35.2)  108 (32.9)  126 (39.8)  
Educational attainment, No. (%)    
≤ Elementary school  101 (31.8)  105 (32.0)  57 (18.0)  
Secondary school  173 (54.4)  182 (55.5)  204 (64.3)   
Higher education  44 (13.8)  41 (12.5)  56 (17.7)LM  
Characteristic, mean (SD)    
Age, y  39.3 (16.0)  40.1 (15.4)  38.2 (13.4)  
Blood pressure, mm Hgb    
Systolic  121.8 (9.7)  121.8 (8.7)  122.0 (9.3)  
Diastolic  74.8 (8.2)  74.0 (7.9)  75.5 (7.7)M  
Weight, kg  74.0 (12.1)  76.1 (11.1)L  78.6 (11.8)LM  
BMI, kg/m2   24.6 (3.4)  24.9 (3.3)  25.2 (3.6)L  
Total cholesterol, mg/dL  206 (47)  206 (47)  205 (48)  
24-hour urinary measurements, mean (SD)       
Duration, h:m  23:51 (01:11)  23:49 (01:11)  23:51 (01:06)  
Volume, L  1.34 (0.61)  1.49 (0.57)L  1.75 (0.61)LM  
Sodium, mmol  121.3 (27.9)  185.3 (16.1)L  282.2 (56.4)LM  
Potassium, mmol  62.5 (26.3)  73.5 (23.4)L  84.1 (28.8)LM   
Sodium-to-potassium ratio  2.19 (0.87)  2.78 (0.97)L  3.74 (1.49)LM  
Creatinine, mmol  12.2 (3.1)  14.1 (3.2)L  16.1 (3.4)LM  
Abbreviation: BMl, body mass index, which is calculated as weight in kilograms divided by height in meters squared.  
Sl conversion factors: To convert millimoles of sodium to grams, multiply by 0.02299; to convert millimoles of potassium to grams, 
multiply by 0.039098; to convert millimoles of creatinine to grams, multiply by 0.11312; cholesterol from mg/dl to mmol/L, 
multiply by 0.0259.  
aThis analysis includes the Hypertension Cohort (n=2096; see Figure 1 and Table 1).  
bFor the blood pressure determination and diabetes mellitus diagnosis, see the "Methods" section.  
P<.05 vs low (L) or middle (M) tertile of 24-hour urinary sodium excretion.    
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eTable 5.  Characteristics of the Participants in the Blood Pressure Cohorta at Baseline and at Follow-up by Country  
Characteristic   
 FLEMENGH
O  
Belgium  
(n=1109)  
Pilsen  
Czech 
Republic  
(n=69)  
Padova  
Italy  
(n=148)   
Kraków  
Poland 
(n=107)  
Novosibirsk 
Russian 
Federation 
(n=66)  
Median follow-up, y 
(IQR)  
 5.59  
(4.87–9.02)  
5.74  
(5.50–5.87)B 
6.99  
(6.60–7.23)  
6.59 
(6.34–6.84)B  
7.69  
(6.94–8.17)C 
Participant characteristics, No. 
(%)  
     
 Women   568 (51.2)  42 (60.9)  79 (53.4)  55 (51.4)  42 (63.6)B  
 Smokers  BL   359 (32.4)  18 (26.1)  39 (26.4)  24 (22.4)B  15 (22.7)  
  FU   307 (27.7)  14 (20.3)  32 (21.6)  25 (23.4)  16 (24.2)  
 Alcohol intake ≥5 
g/day  
BL  216 (19.5)  28 (40.6)B  55 (37.2)B  20 (18.7)CI  26 (39.4)BP  
  FU  345 (31.1)  32 (46.8)B  66 (44.6)B  30 (28.0)CI  20 (30.3)I  
 Contraceptive pill  BL  120 (10.8)  12 (17.4)  15 (10.1)  2 (1.9)BI  4 (6.1)C   
  FU  98 (8.8)  9 (13.0)  0BC  5 (4.7)CI  1 (1.5)BC  
 NSAIDs  BL  146 (13.2)  1 (1.5)B  11 (7.4) B  10 (9.4)C  17 (25.8)BCIP 
  FU  105 (9.5)  8 (11.6)  14 (9.5)  9 (8.4)  4 (6.1)  
Characteristic, mean (SD)       
 Age, y   BL  47.3 (15.2)  38.4 (12.7)B 44.3 (13.2)C 38.6 (13.0)BI  42.2 (13.2)B  
 BMI, kg/m2  BL  24.7 (4.0)  24.6 (4.0)  24.3 (3.6)  24.3 (4.3)  23.7 (4.0)  
  FU  25.6 (4.2)‡  25.4 (4.9)†  25.5 (3.9)‡  25.2 (4.5)  25.4 (4.6)‡  
  Chang
e, y 
0.12 (0.34)  0.14 (0.35)  0.17 (0.29)  0.14 (0.30)  0.23 (0.36)  
 Blood pressure, 
mm Hgb 
      
 Systolic  BL  121.6 (13.0) 116.7 (10.1)B 119.9 (12.6) 120.2 (12.3)  115.8 (10.7)B 
  FU  124.4 (15.1)‡ 116.7 (10.9)B 126.0 
(15.3)C‡   
130.0 
(14.9)BC  
119.3 (14.8)IP*  
  Chang
e, y  
0.22 (2.04)  –0.01 (1.56) 0.87 (1.61)C 1.51 (1.80)BC  0.40 (1.59)IP  
 Diastolic  BL  74.3 (9.0) 74.3 (8.4)  77.2 (8.5)B  75.2 (8.7)  73.4 (8.0)I  
  FU  77.7 (9.4)‡  77.7 (7.6)†  83.5 (9.2)BC‡ 79.0 (9.6)I  77.1 (10.8)I† 
  Chang
e, y  
0.40 (1.55)  0.60 (1.45)  0.91 (1.15)B 0.60 (1.38)  0.46 (1.32)  
24-hour urinary measurements, 
mean (SD)    
     
 Duration, h:m  BL 23:58 (00:50) 24:00 22:12 24:06 (00:43)I  23:57 
© 2011 American Medical Association. All rights reserved. 
 
(00:29)B  (02:01)BC  (00:31)CI  
  FU 23:58 (00:52) 23:40 (00:45) 25:19 
(01:52)BC  
24:01 (00:08)I  23:36 (01:02)I 
 Volume, L  BL 1.58 (0.67)  1.87 (0.67)B 1.27 (0.41)BC 1.43 (0.57)C  1.31 (0.52)BC 
  FU 1.65 (0.73)† 2.09 (0.63)B* 1.72 (0.55)C‡ 1.41 (0.37)BCI  1.39 (0.48)BCI 
 Sodium, mmol  BL 165.2 (58.5) 180.8 (55.9) 172.8 (57.2) 230.2 
(72.6)BCI  
197.5 
(72.9)BIP  
  FU  166.4 (61.4) 188.0 (69.1)B 169.3 (60.8) 188.9 
(68.6)B‡ 
186.8 (66.9) 
  Chang
e, y  
0.057 (11.41) 1.26 (11.10) −0.43 (9.86) −6.27 
(10.75)BCI 
−1.37 (9.43)C 
 Potassium, mmol  BL 69.6 (26.5)  58.5 (20.0)B 60.4 (22.5)B 63.2 (22.2)  59.6 (17.2)B 
  FU  71.3 (25.8)  65.3 (22.3)‡ 68.0 (20.7)‡ 53.3 
(16.9)BCI‡  
59.4 (24.7)B  
  Chang
e, y  
0.40 (4.91) 1.26 (4.47) 1.07 (3.32) −1.39 
(3.68)BCI 
−0.020 (3.48) 
 Creatinine, mmol  BL 12.0 (3.8)  13.0 (3.5)  10.7 (3.0)BC 11.9 (3.6)  10.6 (2.8)BC  
  FU  11.8 (4.0)  11.7 (3.8)‡  12.5 (3.6)‡  12.0 (3.9)  10.6 (3.9)I  
 Chang
e, y  
−0.040 (0.61) −0.24 (0.49)B 0.26 (0.41)BC 0.0048 
(0.51)CI 
0.0039 (0.45)I 
Abbreviations: BMl, body mass index, which is calculated as weight in kilograms divided by height in meters squared; 
FLEMENGHO, the Flemish Study on Environment, Genes, and Health Outcomes; IQR, interquartile range; NSAID, nonsteroidal 
anti-inflammatory drug. BL and FU refer to measurements obtained at baseline and follow-up. In Belgium, BL and FU 
observations were collected from 1985 until 2004 and from 1990 until 2009; in the other countries, these intervals ranged from 
1999 until 2001 and from 2006 until 2008, respectively.   
Sl conversion factors: To convert millimoles of sodium to grams, multiply by 0.02299; to convert millimoles of potassium to grams, 
multiply by 0.039098; to convert millimoles of creatinine to grams, multiply by 0.11312. 
aThis analysis includes the Blood Pressure Cohort (n=1499; see Figure 1 and Table 1).   
bFor the blood pressure determination, see the "Methods" section.  
Significance of the paired differences between BL and FU: *P<.05, †P<.01, ‡P<.001. P-values for between-countries differences 
were adjusted for multiple comparisons (Tukey test): P<.05 vs Belgium (B), the Czech Republic (C), Italy (I), Poland (P).  
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eTable 6.  Causes of Cardiovascular Mortality and Morbidity in the Outcome Cohort.  
 Number of events  
 All  
(n=3681)  
FLEMENGHO 
(n=2674)  
EPOGH  
(n=1007)  
Stroke  Fatal  20  18  2  
 Nonfatal  13  13  …  
Myocardial infarction  Fatal  19  18  1  
 Nonfatal  27  19  8  
Acute coronary syndrome  Nonfatal   4  4  …  
Ischemic heart disease  Fatal  6  6  …  
 Nonfatal  3  3  …  
Sudden death  Non-
resuscitated  
6  6  …  
Coronary revascularization  Surgical  20  13  7  
 Percutaneous  13  13  …  
Heart failure  Fatal  29  29  …  
 Nonfatal  43  37  6  
Arterial embolism  Fatal  1  1   …  
Pulmonary embolism  Fatal  2  2  …  
 Nonfatal  9  9  …  
Aortic aneurysm  Fatal  1  1  …  
 Nonfatal  2  2  …  
Pulmonary heart disease  Nonfatal  14  14  …  
Abbreviations: EPOGH, the European Project on Genes in Hypertension; FLEMENGHO, the Flemish Study on 
Environment, Genes, and Health Outcomes.  
This analysis includes the Outcome Cohort (n=3681; see Figure 1 and Table 1).   
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eTable 7.   Multivariable-Adjusted Hazard Ratios for Mortality and Cardiovascular Events by Tertiles of the 24-Hour Urinary Sodium Excretion at Baseline in 
3194 Participants Younger Than 60 Years.   
 24-Hour Urinary Sodium Excretion Tertiles   
 Low   
(n=1059)  
Medium  
(n=1082)  
High  
(n=1053)  
 
No. of women  556  573  555  
 Range, mmol 50–129  130–180 181–400   
 Mean (SD), mmol  97.3 (22.7)  153.3 (15.1)  235.1 (51.3)   
No. of men 503 509 498  
 Range, mmol 50–162  163–227 228–400   
 Mean (SD), mmol  122.3 (28.7)  193.2 (17.6)  296.4 (55.2)  
 Total No. 
of Events  
No. of 
Events 
Adjusted HR 
(95% CI)a  
No. of 
Events 
Adjusted HR 
(95% CI)a  
No. of 
Events 
Adjusted HR 
(95% CI)a  
 P 
 Value  
Mortality          
 All causes  77  30  0.98 (0.68 to 1.41) 28  1.05 (0.76 to 1.46) 19  0.95 (0.69 to 1.31)  .71  
 Cardiovascular  16  8  1.41 (0.70 to 2.83)  7  1.32 (0.67 to 2.58)  3  0.76 (0.39 to 1.49)  .61  
 Noncardiovascular  59  22  0.91 (0.59 to 1.38)  21  1.01 (0.69 to 1.46)  16  0.99 (0.68 to 1.44)  .56  
Fatal and nonfatal events          
 All cardiovascular  134  53  1.12 (0.86 to 1.46)  45  1.09 (0.84 to 1.41)  36  0.92 (0.71 to 1.19)  .57  
 Coronary  60  27  1.35 (0.88 to 2.07)  20  1.09 (0.76 to 1.56)  13  0.92 (0.64 to 1.32)  .14  
 Stroke  11 3    0.64 (0.24 to 1.70)  4  1.23 (0.46 to 3.32)  4  0.81 (0.30 to 2.18)  .18  
Abbreviations: Cl, confidence interval; HR, hazard ratio.  
This analysis includes the 3194 participants from the Outcome Cohort (see Figure 1 and Table 1), who were younger than 60 years.  
aHRs were computed by deviation from mean coding and express the risk in each tertile of the distribution of 24-hour urinary sodium excretion at baseline compared with the overall 
risk in the whole group. We applied Cox proportional hazard regression to derive HRs, while adjusting for covariables and accounting for family clusters. All HRs were adjusted for 
study population, sex and baseline variables: age, body mass index, systolic blood pressure, 24-hour urinary potassium excretion, antihypertensive drug treatment, smoking and 
drinking alcohol, diabetes, total cholesterol, and educational attainment. Adjustment for diastolic blood pressure or mean arterial pressure instead of systolic blood pressure did not 
materially alter the findings.  
P-values are for linear trend across the tertiles of 24-hour sodium excretion.   
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eTable 8.   Multivariable-Adjusted Hazard Ratios for Mortality and Cardiovascular Events by Tertiles of the 24-Hour Urinary Sodium Excretion at Baseline in 487 
Participants 60 Years or Older.   
 24-Hour Urinary Sodium Excretion Tertiles   
 Low   
(n=1059)  
Medium  
(n=1082)  
High  
(n=1053)  
 
No. of women  85  88  84   
 Range, mmol 50–109  110–155  156–345   
 Mean (SD), mmol  82.9 (16.9)  129.5 (11.5)  203.7 (45.9)   
No. of men 76  79  75   
 Range, mmol 50–138  139–192  193–400   
 Mean (SD), mmol  105.2 (26.8)  164.7 (15.0)  244.0 (51.3)   
 Total No. 
of Events  
No. of 
Events 
Adjusted HR 
(95% CI)a  
No. of 
Events 
Adjusted HR 
(95% CI)a  
No. of 
Events 
Adjusted HR 
(95% CI)a  
 P 
 Value  
Mortality          
 All causes  142  64  1.26 (0.90 to 1.75)  49  1.05 (0.80 to 1.37)  29  0.96 (0.73 to 1.25)  .14  
 Cardiovascular  66  31  1.52 (0.94 to 2.47)  22  1.06 (0.73 to 1.56)  13  0.94 (0.64 to 1.37)  .056  
 Noncardiovascular  76  33  1.12 (0.73 to 1.71)  27  1.06 (0.75 to 1.49)  16  0.95 (0.67 to 1.34)  .68  
Fatal and nonfatal events          
 All cardiovascular  98  39  1.09 (0.77 to 1.56)  32  0.90 (0.67 to 1.21)  27  1.11 (0.83 to 1.50)  .28  
 Coronary  38  16  1.05 (0.57 to 1.93)  11  0.75 (0.46 to 1.24)  11  1.33 (0.80 to 2.20)  .40  
 Stroke  22  9  0.85 (0.42 to 1.75)  6  0.73 (0.41 to 1.32)  7  1.36 (0.76 to 2.45)  .90  
Abbreviations: Cl, confidence interval; HR, hazard ratio.  
This analysis includes the 487 participants from the Outcome Cohort (see Figure 1 and Table 1), who were 60 years or older.  
aHRs were computed by deviation from mean coding and express the risk in each tertile of the distribution of 24-hour urinary sodium excretion at baseline compared with the overall 
risk in the whole group. We applied Cox proportional hazard regression to derive HRs, while adjusting for covariables and accounting for family clusters. All HRs were adjusted for 
study population, sex and baseline variables: age, body mass index, systolic blood pressure, 24-hour urinary potassium excretion, antihypertensive drug treatment, smoking and 
drinking alcohol, diabetes, total cholesterol, and educational attainment. Adjustment for diastolic blood pressure or mean arterial pressure instead of systolic blood pressure did not 
materially alter the findings.  
P-values are for linear trend across the tertiles of 24-hour sodium excretion.   
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eTable 9.  Multivariable-Adjusted Hazard Ratios for Mortality and Cardiovascular Events by Tertiles of the 24-Hour Urinary Sodium Excretion at Baseline 
Excluding Any Adjustment for Blood Pressure  
 24-Hour Urinary Sodium Excretion Tertiles   
 Low  
(n=1220)  
Medium  
(n=1250)  
High  
(n=1211)  
 
No. of women  645  658  638   
 Range, mmol 50–126  127–177  178–400   
 Mean (SD), mmol  95.1 (22.0)  150.2 (15.0)  231.7 (50.9)   
No. of men 575 592 573  
 Range, mmol 50–158  159–221  222–400   
 Mean (SD), mmol  120.1 (28.4)  188.8 (17.6)  290.5 (56.2)   
 Total No. 
of Events  
No. of 
Events 
Adjusted HR 
(95% CI)a  
No. of 
Events  
Adjusted HR 
(95% CI)a  
No. of 
Events 
Adjusted HR 
(95% CI)a  
 P 
 Value  
Mortality          
  All causes  219 118  1.12 (0.86 to 1.45)  64  0.93 (0.74 to 1.16)  37  1.08 (0.87 to 1.35)  .10  
  Cardiovascular  84 50  1.41 (0.94 to 2.12)  24  0.98 (0.69 to 1.40)  10  1.02 (0.71 to 1.45)  .034  
  Noncardiovascular  135 68  0.99 (0.71 to 1.36)  40  0.91 (0.68 to 1.20)  27  1.10 (0.83 to 1.47)  .64  
Fatal and nonfatal events         
  All cardiovascular  232 100  1.12 (0.90 to 1.41)  79  1.09 (0.89 to 1.34)  53  0.92 (0.74 to 1.13)  .54  
  Coronary  98 45  1.41 (0.99 to 2.01)  34  1.15 (0.87 to 1.52)  19  0.87 (0.66 to 1.15)  .093  
  Stroke  33 13  1.05 (0.56 to 1.96)  13  1.28 (0.75 to 2.17)  7  0.78 (0.46 to 1.33)  .61  
Abbreviations: Cl, confidence interval; HR, hazard ratio. 
This analysis includes the Outcome Cohort (n=3681; see Figure 1 and Table 1).   
aHRs were computed by deviation from mean coding and express the risk in each tertile of the distribution of 24-hour urinary sodium excretion at baseline compared with the overall risk in the whole group. We applied Cox proportional 
hazard regression to derive HRs, while adjusting for covariables and accounting for family clusters. All HRs were adjusted for study population, sex and baseline variables: age, body mass index, 24-hour urinary potassium excretion, 
antihypertensive drug treatment, smoking and drinking alcohol, diabetes, total cholesterol, and educational attainment.   
P-values are for linear trend across the tertiles of 24-hour sodium excretion.   
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eTable 10.−Multivariable-Adjusted Hazard Ratios for Mortality and Cardiovascular Events by Tertiles of the 24-Hour Urinary Sodium-to-
Potassium Ratio at Baseline. 
 24-Hour Urinary Sodium Excretion Tertiles   
 Low  
(n=1241)  
Medium  
(n=1232)  
High  
(n=1208)  
 
No. of women 653  649  639   
 Range, mmol 0.8–2.1  2.2–3.1  3.2–6.0   
 Mean (SD), mmol  1.64 (0.36)  2.59 (0.27)  4.15 (0.86)   
No. of men  588  583  569   
 Range, mmol 0.8–2.3  2.4–3.3 3.4–6.0   
 Mean (SD), mmol  1.75 (0.41)  2.80 (0.28)  4.37 (0.84)   
 Total No. 
of Events  
No. of  
Events 
Adjusted HR 
(95% CI)a  
No. of 
Events 
Adjusted HR 
(95% CI)a  
No. of 
Events 
Adjusted HR 
(95% CI)a  
 P 
 Value 
Mortality          
 All causes  219  94  1.25 (1.00 to 1.57)  78  1.09 (0.90 to 1.33) 47  0.91 (0.75 to 1.12) .063  
 Cardiovascular 84  41  1.61 (1.06 to 2.45)* 28  1.13 (0.79 to 1.61) 15  0.89 (0.62 to 1.27) .0069 
 Noncardiovascula
r  
135  53  1.10 (0.85 to 1.44)  50  1.10 (0.86 to 1.40) 32  0.91 (0.71 to 1.16) .72  
Fatal and nonfatal events          
 All cardiovascular  232  93  1.26 (1.00 to 1.52)  89  1.09 (0.89 to 1.33) 50  0.92 (0.75 to 1.12) .066  
 Coronary  98  42  1.31 (0.94 to 1.84)  33  0.97 (0.73 to 1.30) 23  1.03 (0.77 to 1.37) .035  
 Stroke  33  15  1.32 (0.73 to 2.41)  12  0.99 (0.60 to 1.65) 6  1.01 (0.61 to 1.66) .25  
Abbreviations: Cl, confidence interval; HR, hazard ratio. 
This analysis includes the Outcome Cohort (n=3681; see Figure 1 and Table 1).   
aHRs were computed by deviation from mean coding and express the risk in each tertile of the distribution of the 24-hour urinary sodium-to-potassium ratio at baseline compared with the overall risk in the whole group. We applied Cox 
proportional hazard regression to derive HRs, while adjusting for covariables and accounting for family clusters. All HRs were adjusted for study population, sex and baseline variables: age, body mass index, systolic blood pressure, 
antihypertensive drug treatment, smoking and drinking alcohol, diabetes, total cholesterol, and educational attainment. Adjustment for diastolic blood pressure or mean arterial pressure instead of systolic blood pressure did not 
materially alter the findings.   
P-values are for linear trend across the tertiles of the 24-hour sodium-to-potassium ratio.   
Significance of the HRs: *P=.025  
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eTable 11.   Multivariable-Adjusted Hazard Ratios for Cardiovascular Mortality by Tertiles of the 24-Hour Urinary Sodium Excretion at 
Baseline with Censoring of Follow-up at 6, 9, 12, 15, 18 and 21 Years.  
 24-Hour Urinary Sodium Excretion Tertiles   
 Low  
(n=1220)  
Medium  
(n=1250)  
High  
(n=1211)  
 
 No. of 
Events 
Adjusted HR     
(95% CI)a  
No. of 
Events 
Adjusted HR     
(95% CI)a  
No. of 
Events 
Adjusted HR     
(95% CI)a  
P  
Value 
Model censored at          
 6 years  16  1.65 (0.85 to 3.22)  9  1.91 (0.90 to 4.08)  4  0.52 (0.25 to 1.12)  .80  
 9 years  25  1.20 (0.54 to 2.63)  13  1.25 (0.57 to 2.76)  8  0.80 (0.36 to 1.76)  .98  
 12 years  29  1.61 (0.77 to 3.35)  18  1.56 (0.85 to 2.87)  8  0.64 (0.35 to 1.18)  .69  
 15 years  36  1.68 (0.88 to 3.20)  19  1.39 (0.84 to 2.32)  9  0.72 (0.43 to 1.19)  .33  
 18 years  42  1.66 (1.00 to 2.75)*  21  1.16 (0.77 to 1.74)  9  0.87 (0.58 to 1.30)  .049  
 21 years  50  1.56 (1.02 to 2.36)*  24  1.05 (0.72 to 1.53)  10  0.95 (0.66 to 1.38)  .020  
Abbreviations: Cl, confidence interval; HR, hazard ratio. 
This analysis includes the Outcome Cohort (n=3681; see Figure 1 and Table 1).   
aHazard ratios were computed by deviation from mean coding and express the risk in each tertile of the distribution of 24-hour urinary sodium excretion at 
baseline compared with the overall risk in the whole group.  We applied Cox proportional hazard regression to derive HRs, while adjusting for covariables 
and accounting for family clusters. All HRs were adjusted for study population, sex and baseline variables: age, body mass index, systolic blood pressure, 24-
hour urinary potassium excretion, antihypertensive drug treatment, smoking and drinking alcohol, diabetes, total cholesterol, and educational attainment. 
Adjustment for diastolic blood pressure or mean arterial pressure instead of systolic blood pressure did not materially alter the findings.  
P-values are for linear trend across the tertiles of 24-hour sodium excretion.   
Significance of the HRs: *P.048  
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eTable 12.   Multivariable-Adjusted Hazard Ratios for Incidence of Hypertension by Tertiles of the 24-Hour Urinary Sodium Excretion at 
Baseline.   
 24-Hour Urinary Sodium Excretion Tertiles   
 Low  
(n=693)   
Medium  
(n=713)  
High 
(n=690)  
 
No. of women 375  385  373   
 Range, mmol 50–124  125–173  174–400   
 Mean (SD), mmol  94.7 (21.5)  147.4 (14.3)  222.1 (47.2)   
No. of men 318 328 317  
 Range, mmol 50–157  158–214  215–400   
 Mean (SD), mmol  121.3 (27.9)  185.3 (16.1)  282.2 (56.4)   
 No. of 
Events 
Adjusted HR    
(95% CI)a  
No. of 
Events 
Adjusted HR    
(95% CI)a  
No. of 
Events  
Adjusted HR    
(95% CI)a  
P  
 Value  
Study population         
 FLEMENGHO (434)  163  1.00 (0.84 to 1.19)  155  1.00 (0.86 to 1.16)  116  1.00 (0.86 to 1.16) .97  
 EPOGH (118)  24  0.98 (0.76 to 1.27)  35  1.20 (0.89 to 1.62)  59  0.83 (0.62 to 1.12) .55  
 All (552)  187  1.00 (0.87 to 1.16)  190  1.02 (0.89 to 1.16)  175  0.98 (0.86 to 1.12) .93  
Abbreviations: Cl, confidence interval; EPOGH, the European Project on Genes and Hypertension; FLEMENGHO, Flemish Study on Environment, Genes and 
Health Outcomes; HR, hazard ratio.  
This analysis includes the Hypertension Cohort (n=2096; see Figure 1 and Table 1). At baseline, all subjects belonging to the Hypertension Cohort were 
untreated. Hypertension during follow-up was a blood pressure of 140 mm Hg systolic or 90 mm Hg diastolic or more or use of antihypertensive drugs.   
aHazard ratios were computed by deviation from mean coding and express the risk in each tertile of the distribution of 24-hour urinary sodium excretion at 
baseline compared with the overall risk in the whole group. We applied Cox proportional hazard regression to derive HRs, while adjusting for covariables 
and accounting for family clusters.  All HRs were adjusted for study population, sex and baseline variables: age, body mass index, systolic blood pressure, 
24-hour urinary potassium excretion, drinking alcohol, and educational attainment.  HRs in all participants combined were additionally adjusted for study 
population.  
P-values are for linear trend across the tertiles of 24-hour sodium excretion.   
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eTable 13.  Multivariable-Adjusted Cross-Sectional Associations Between Blood Pressure and 24-Hour Urinary Sodium by Study Population 
and Study Phasea  
Study Population   Baseline   Follow-Up  
   Estimates (95% CI)b  P   Estimates (95% CI)b  P  
Systolic Pressure        
 FLEMENGHO   0.525 (–0.793 to 1.843)  .43   2.002 (0.487 to 3.517)  .01  
 EPOGH   2.109 (0.282 to 3.937)  .02   −0.019 (−2.210 to 2.201)  .99  
 All   1.140 (0.055 to 2.224)  .04   1.459 (0.208 to 2.710)  .02  
Diastolic Pressure        
 FLEMENGHO   0.534 (–0.389 to 1.456)  .25   0.258 (–0.734 to 1.251)  .61  
 EPOGH   1.004 (–0.339 to 2.347)  .14   –0.324 (–1.865 to 1.217)  .68  
 All   0.739 (–0.025 to 1.500)  .16   0.090 (–0.724 to 0.942)  .80  
Abbreviations: Cl, confidence interval; EPOGH, the European Project on Genes in Hypertension; FLEMENGHO is the Flemish Study on Environment, Genes, 
and Health Outcomes.  
aReasons for exclusion from analysis are explained in the "Methods" section.  
bEstimates and 95% CIs express the difference in blood pressure associated with a 100 mmol increase in 24-hour urinary sodium excretion.  All parameter 
estimates were adjusted for sex, age, body mass index, alcohol intake (0,1), 24-hour urinary potassium excretion, use of female sex hormones (0,1), and 
nonsteroidal anti-inflammatory drugs (0,1), and account for family clusters. Estimates in all participants combined were additionally adjusted for study 
population.   
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eFigure 1. Incidence of Mortality and All Cardiovasular Events 
 
 
Incidence of mortality (A) and cardiovascular events (B) by tertiles of the distributions of the 24-hour urinary sodium excretion at baseline. This analysis includes the Outcome 
Cohort (n=3681; see Figure 1 and Table 1). Incidence rates were standardized for study population, sex, and age by the direct method. The number of events contributing to the 
rates is presented. CV and Non-CV indicate cardiovascular and noncardiovascular mortality, respectively. The data markers are centered to the means of the 24-hour urinary 
sodium excretion in each tertile of the distribution. For the mean and range of the 24-hour sodium excretion in each tertile, see Table 2. The P-values are for linear trend across 
the tertiles of the 24-hour sodium excretion and were computed using Cox proportional regression models with study population, sex and age at baseline as covariables. 
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eFigure 2. Kaplan-Meier Estimates for the Incidence of Hypertension by Tertiles of 
the 24-Hour Urinary Sodium Excretion at Baseline  
 
 
 
This analysis includes the Hypertension Cohort (n=2096; see Figure 1 and Table 1). Tertiles of the 24-hour urinary sodium 
excretion are sex-specific based on baseline measurements. For the mean and range of the 24-hour sodium excretion in each 
tertile, see eTable 12.   
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eFigure 3. Distribution of the Absolute (A, C, E) and Relative (B, D, F) 
Changes in Systolic Blood Pressure (A, B), Diastolic Blood Pressure (C, D), and 
24-hour Urinary Sodium Excretion (E, F) in 1499 Participants of the Blood 
Pressure Cohort Followed Up for a Median of 6.1 Years  
 
 
Distributions are represented by frequencies for given intervals and by a continuous line, which was fitted by means of the 
distribution density modeling software available in the SAS JMP add-on, version 8.0. All distributions were positively skewed 
(0.08) and departed from normality (Shapiro-Wilk statistic 0.92; P<.0001).   
© 2011 American Medical Association. All rights reserved. 
 
eFigure 4. Change in Systolic Blood Pressure During Follow-Up By Deciles of 
the Change in the 24-Hour Urinary Sodium Excretion in the Blood Pressure 
Cohort (n=1499)   
 
The data markers are centered on the means in each decile. The analyses were adjusted for study population, sex, baseline values of and changes in: 
age, body mass index, alcohol intake (stopping, no change and starting coded as –1, 0,1), 24-hour urinary potassium excretion, use of female sex hormones (–1, 0,1), and 
non-steroidal anti-inflammatory drugs (–1, 0,1), and account for family clusters. Changes are expressed in absolute units (A) or as percentage changes (B). The P-values 
are for linear trend. Dotted lines represent the regression line and the 95% confidence interval for the changes in systolic blood pressure across deciles. Mean values and 
limits of the changes in the 24 hour urinary sodium excretion from the bottom to top decile: Panel A: −113 (−159 to −90), −72 (−89 to −60), −50 (−59 to −42), −32 (−41 to 
−24), −14 (−23 to −5), +3 (−4 to +13), +23 (+14 to +33), +44 (+34 to +57), +74 (+58 to +90), +114 (+91 to +159); Panel B: −51(−72 to −43), −36 (−42 to −32), −26 (−31 
to −23), −18 (−22 to −14),  
−8 (−13 to −4), +3 (−3 to +9), +16 (+9 to +22), +32 (+23 to +42), +55 (+43 to +73), +107 (+74 to +230).
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eFigure 5. Change in Diastolic Blood Pressure During Follow-Up by Deciles of 
the Change in 24-Hour Urinary Sodium Excretion in the Blood Pressure Cohort 
(n=1499). 
 
 
The data markers are centered to the means in each decile. Changes are expressed in absolute units (A) or as percentage changes (B). 
The P-values are for linear trend. Dotted lines represent the regression line and 95% confidence interval for the changes in diastolic blood pressure 
across deciles. For adjustments and range of deciles, see eFigure 4.    
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